HS 10381
Alternative Names: HS-10381Latest Information Update: 22 Jul 2022
At a glance
- Originator Jiangsu Hansoh Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein tyrosine phosphatase non receptor type 11 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 08 Jun 2022 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (PO) (NCT05378178)
- 19 May 2022 Jiangsu Hansoh Pharmaceutical plans a first-in-man phase I trial for Solid tumours (Late-stage disease) in China (PO) (NCT05378178)